Pelthos Therapeutics Inc. Deferred Offering Costs
Pelthos Therapeutics Inc. (PTHS) had Deferred Offering Costs of $0 as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-13
- 2026-06-30: Deferred Offering Costs $0.00.
- 2026-03-31: Deferred Offering Costs $711.00K.
- 2025-12-31: Deferred Offering Costs $711.00K.
- 2025-09-30: Deferred Offering Costs $711.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 |
| 2026-03-31 | $711.00K 10-Q/A · filed 2026-08-13 |
| 2025-12-31 | $711.00K 10-Q/A · filed 2026-08-13 |
| 2025-09-30 | $711.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $710.94K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $723.13K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $750.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $750.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |